Skip to main content
Clinical Trials/NCT05526300
NCT05526300
Completed
Not Applicable

Randomized Study of Antihypertensive Intervention by Intelligent Hypertension Management System

Shanghai Tong Ren Hospital3 sites in 1 country320 target enrollmentSeptember 6, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
To Explore Whether the Application of Intelligent Hypertension Management System Can Effectively Reduce Blood Pressure in Hypertensive Patients
Sponsor
Shanghai Tong Ren Hospital
Enrollment
320
Locations
3
Primary Endpoint
Net change in systolic blood pressure from baseline to 3 months follow-up
Status
Completed
Last Updated
11 months ago

Overview

Brief Summary

To explore whether the application of intelligent hypertension management system can effectively reduce blood pressure in hypertensive patients. A total of 320 eligible subjects will be recruited and randomization to two groups. The standard care group (n=160) will receive conventional hypertension treatment with baseline data collected.Wearable blood pressure monitoring device management group (intervention group, n=160) will receive blood pressure monitoring remotely everyday and antihypertension medication treatment. Primary outcome is Net change in systolic blood pressure from baseline to 3 months follow-up. Secondary outcomes include Net change in diastolic blood pressure hypertension control ratio (BP < 140/90 mmHg)

Registry
clinicaltrials.gov
Start Date
September 6, 2022
End Date
December 1, 2024
Last Updated
11 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Shanghai Tong Ren Hospital
Responsible Party
Principal Investigator
Principal Investigator

Hou Lei

Director of cardiovascular disease institute

Shanghai Tong Ren Hospital

Eligibility Criteria

Inclusion Criteria

  • Aged more than 18 years old, less than or equal to 75 years old.
  • Hypertensive patients (systolic/diastolic blood pressure ≥140/90 mmHg at two separate screening/baseline visits)
  • Patients or guardians can skillfully use devices such as smartphones and electronic sphygmomanometers
  • Voluntarily joined and signed the informed consent

Exclusion Criteria

  • Pregnant women or women planning to become pregnant within the next year;
  • Patients with secondary hypertension
  • Patients with life expectancy less than 1 year
  • Severe hepatic and renal insufficiency (ALT \> 5 times ULA, eGFR \< 15ml/min/1.73mm2)
  • Known active malignancy disease
  • The researcher believes that patients who are not suitable to participate in this study

Outcomes

Primary Outcomes

Net change in systolic blood pressure from baseline to 3 months follow-up

Time Frame: one and three months after study

Secondary Outcomes

  • Net change in diastolic blood pressure(one and three months after study)
  • Hypertension control ratio (BP < 140/90 mmHg)(one and three months after study)

Study Sites (3)

Loading locations...

Similar Trials